Evercore ISI reiterates IBM stock rating on Q1 beat expectations

Evercore ISI reiterated an Outperform rating and $345 price target on IBM ahead of its April 22 Q1 earnings, expecting revenue of $15.6 billion and EPS of $1.81 to come in above consensus. The firm also sees IBM raising its 2026 constant-currency revenue growth outlook above 5%, with software growth above 10%, helped by Red Hat reacceleration and an earlier-than-expected Confluent contribution. IBM’s $12.1 billion in levered free cash flow and 2.65% dividend yield support the constructive view, while AI and cybersecurity initiatives remain key strategic catalysts.

Analysis

IBM is setting up as a classic pre-earnings compression trade where the market is anchoring to a slower-growth software story while the setup has more moving pieces than the headline implies. The key second-order effect is that even modest upside in software can matter disproportionately because IBM’s multiple is still being held down by lingering skepticism around organic growth quality; that makes any guide-up on constant-currency revenue or free cash flow a catalyst for multiple expansion, not just estimate beats.

The market may also be underestimating the operating leverage from mix. If Confluent contributes earlier than modeled and software re-accelerates, the incremental dollars should be high-margin and partly offset FX drag, which means reported growth can look mediocre while cash generation inflects harder than consensus expects. That combination is important because IBM’s dividend and buyback credibility reduce downside on a miss, but also cap the magnitude of a selloff unless management sounds vague on 2026 visibility.

The contrarian issue is that this is not a clean “earnings beat = stock up” setup; the real risk is a quality-of-guidance disappointment. If management leans conservative on 2026 or fails to show clear evidence that AI and consulting are converting into durable backlog, the stock can de-rate even on a beat, because investors will interpret it as another short-lived proof point rather than a structural turn. Longer-term, the market is likely pricing too little value for IBM’s cash return profile if FCF stays above guided levels, but too much value if the software re-acceleration thesis is mostly a re-bundling of existing products rather than true net new demand.

Key Decisions for Investors

• Go long IBM into earnings via a call spread or stock position sized for event risk; best risk/reward is 2-6 week horizon if management raises 2026 constant-currency growth and FCF, with upside to a mid-teens re-rating if guidance improves.
• If already long IBM, hedge into the print with short-dated puts rather than selling core exposure; the main downside is a guide miss or cautious 2026 tone, not the quarter itself.
• Pair trade: long IBM / short a lower-quality legacy enterprise software name over the next 1-3 months; IBM’s dividend-supported downside and credible cash conversion make it the cleaner earnings-quality trade if guidance improves.
• Avoid chasing CFLT here unless the report explicitly shows meaningful incremental IBM-related monetization; the better expression is IBM as the acquirer-beneficiary, not a standalone momentum bet on the target.
• On any post-earnings gap higher, take partial profits into strength unless management quantifies AI/consulting backlog conversion; the stock likely needs evidence, not just narrative, to hold a higher multiple.